Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study

Monique K van der Kooij; Olaf M Dekkers; Maureen J B Aarts; Franchette W P J van den Berkmortel; Marye J Boers-Sonderen; Jan Willem B de Groot; Geke A P Hospers; Djura Piersma; Rozemarijn S van Rijn; Karijn P M Suijkerbuijk; Hans M Westgeest; Astrid A M van der Veldt; Gerard Vreugdenhil; Sofie Wilgenhof; Michel W J M Wouters; John B A G Haanen; Alfonsus J M van den Eertwegh; Ellen Kapiteijn

doi:10.3390/cancers13184639

Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study

Monique K van der Kooij, Olaf M Dekkers, Maureen J B Aarts, Franchette W P J van den Berkmortel, Marye J Boers-Sonderen, Jan Willem B de Groot, Geke A P Hospers, Djura Piersma, Rozemarijn S van Rijn, Karijn P M Suijkerbuijk, Hans M Westgeest, Astrid A M van der Veldt, Gerard Vreugdenhil, Sofie Wilgenhof, Michel W J M Wouters, John B A G Haanen, Alfonsus J M van den Eertwegh, Ellen Kapiteijn^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

13 Citations (Scopus)

18 Downloads (Pure)

Abstract

Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013-July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3-4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients ≥60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference.

Original language	English
Journal	Cancers
Volume	13
Issue number	18
DOIs	https://doi.org/10.3390/cancers13184639
Publication status	Published - 16 Sept 2021

Bibliographical note

Funding:
This research received no external funding. The Netherlands Organization for Health
Research and Development funded the start-up of the Dutch Melanoma Treatment Registry (DMTR).
Grant number: 836002002. This grant was awarded under the effectiveness research for high-cost
medicine program. From its foundation, the DMTR has been sponsored by BMS, Novartis, Roche
Nederland B.V., MSD, Pierre Fabre and the health insurance companies in the Netherlands via the
Dutch Institute for Clinical Auditing (DICA).

Access to Document

10.3390/cancers13184639Licence: CC BY

Sex-Based Differences inFinal published version, 518 KBLicence: CC BY

Cite this

van der Kooij, M. K., Dekkers, O. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Boers-Sonderen, M. J., de Groot, J. W. B., Hospers, G. A. P., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Westgeest, H. M., van der Veldt, A. A. M., Vreugdenhil, G., Wilgenhof, S., Wouters, M. W. J. M., Haanen, J. B. A. G., van den Eertwegh, A. J. M., & Kapiteijn, E. (2021). Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. Cancers, 13(18). https://doi.org/10.3390/cancers13184639

@article{338580f582854b01b261fe0adfbb7dd9,

title = "Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study",

abstract = "Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013-July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3-4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients ≥60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference.",

author = "{van der Kooij}, {Monique K} and Dekkers, {Olaf M} and Aarts, {Maureen J B} and {van den Berkmortel}, {Franchette W P J} and Boers-Sonderen, {Marye J} and {de Groot}, {Jan Willem B} and Hospers, {Geke A P} and Djura Piersma and {van Rijn}, {Rozemarijn S} and Suijkerbuijk, {Karijn P M} and Westgeest, {Hans M} and {van der Veldt}, {Astrid A M} and Gerard Vreugdenhil and Sofie Wilgenhof and Wouters, {Michel W J M} and Haanen, {John B A G} and {van den Eertwegh}, {Alfonsus J M} and Ellen Kapiteijn",

note = "Funding: This research received no external funding. The Netherlands Organization for Health Research and Development funded the start-up of the Dutch Melanoma Treatment Registry (DMTR). Grant number: 836002002. This grant was awarded under the effectiveness research for high-cost medicine program. From its foundation, the DMTR has been sponsored by BMS, Novartis, Roche Nederland B.V., MSD, Pierre Fabre and the health insurance companies in the Netherlands via the Dutch Institute for Clinical Auditing (DICA).",

year = "2021",

month = sep,

day = "16",

doi = "10.3390/cancers13184639",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "18",

}

van der Kooij, MK, Dekkers, OM, Aarts, MJB, van den Berkmortel, FWPJ, Boers-Sonderen, MJ, de Groot, JWB, Hospers, GAP, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, Westgeest, HM, van der Veldt, AAM, Vreugdenhil, G, Wilgenhof, S, Wouters, MWJM, Haanen, JBAG, van den Eertwegh, AJM & Kapiteijn, E 2021, 'Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study', Cancers, vol. 13, no. 18. https://doi.org/10.3390/cancers13184639

TY - JOUR

T1 - Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma

T2 - A Nationwide Cohort Study

AU - van der Kooij, Monique K

AU - Dekkers, Olaf M

AU - Aarts, Maureen J B

AU - van den Berkmortel, Franchette W P J

AU - Boers-Sonderen, Marye J

AU - de Groot, Jan Willem B

AU - Hospers, Geke A P

AU - Piersma, Djura

AU - van Rijn, Rozemarijn S

AU - Suijkerbuijk, Karijn P M

AU - Westgeest, Hans M

AU - van der Veldt, Astrid A M

AU - Vreugdenhil, Gerard

AU - Wilgenhof, Sofie

AU - Wouters, Michel W J M

AU - Haanen, John B A G

AU - van den Eertwegh, Alfonsus J M

AU - Kapiteijn, Ellen

N1 - Funding: This research received no external funding. The Netherlands Organization for Health Research and Development funded the start-up of the Dutch Melanoma Treatment Registry (DMTR). Grant number: 836002002. This grant was awarded under the effectiveness research for high-cost medicine program. From its foundation, the DMTR has been sponsored by BMS, Novartis, Roche Nederland B.V., MSD, Pierre Fabre and the health insurance companies in the Netherlands via the Dutch Institute for Clinical Auditing (DICA).

PY - 2021/9/16

Y1 - 2021/9/16

N2 - Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013-July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3-4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients ≥60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference.

AB - Recent meta-analyses show conflicting data on sex-dependent benefit following systemic treatment for advanced melanoma patients. We examined the nationwide Dutch Melanoma Treatment Registry (July 2013-July 2018), assessing sex-dependent differences in advanced melanoma patients (stage IIIC/IV) with respect to clinical characteristics, mutational profiles, treatments initiated, grade 3-4 adverse events (AEs), treatment responses, and mortality. We included 3985 patients, 2363 men (59%) and showed that although men and women with advanced melanoma differ in clinical and tumor characteristics, the safety profile of immune checkpoint inhibition (ICI) is comparable. The data suggest a 10% survival advantage for women, mainly seen in patients ≥60 years of age and patients with BRAF V600 mutant melanoma. Following ICI there was no survival difference.

U2 - 10.3390/cancers13184639

DO - 10.3390/cancers13184639

M3 - Article

C2 - 34572865

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 18

ER -

Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this